314 related articles for article (PubMed ID: 26874851)
21. High level of CXCR4 in triple-negative breast cancer specimens associated with a poor clinical outcome.
Yu S; Wang X; Liu G; Zhu X; Chen Y
Acta Med Okayama; 2013; 67(6):369-75. PubMed ID: 24356721
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features.
Astvatsaturyan K; Yue Y; Walts AE; Bose S
PLoS One; 2018; 13(6):e0197827. PubMed ID: 29883487
[TBL] [Abstract][Full Text] [Related]
23. Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.
Harrasser M; Gohil SH; Lau H; Della Peruta M; Muczynski V; Patel D; Miranda E; Grigoriadis K; Grigoriadis A; Granger D; Evans R; Nathwani AC
Breast Cancer Res; 2022 Jun; 24(1):39. PubMed ID: 35659040
[TBL] [Abstract][Full Text] [Related]
24. Girdin protein expression is associated with poor prognosis in patients with invasive breast cancer.
Choi JS; Kim KH; Oh E; Shin YK; Seo J; Kim SH; Park S; Choi YL
Pathology; 2017 Oct; 49(6):618-626. PubMed ID: 28818465
[TBL] [Abstract][Full Text] [Related]
25. Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer.
Kim YJ; Sung M; Oh E; Vrancken MV; Song JY; Jung K; Choi YL
Cancer Biol Ther; 2018 Apr; 19(4):335-345. PubMed ID: 29333926
[TBL] [Abstract][Full Text] [Related]
26. Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer.
Bahhnassy A; Mohanad M; Shaarawy S; Ismail MF; El-Bastawisy A; Ashmawy AM; Zekri AR
Mol Med Rep; 2015 Jul; 12(1):851-64. PubMed ID: 25824321
[TBL] [Abstract][Full Text] [Related]
27. [Clinicopathologic features and prognosis of triple negative breast cancer].
Zhou T; Yang L; Ma GM; Li CX; Bai Y; Zhao JA; Wang XL; Geng CZ
Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(32):2261-4. PubMed ID: 20095338
[TBL] [Abstract][Full Text] [Related]
28. Novel prognostic markers for patients with triple-negative breast cancer.
Zhou L; Li K; Luo Y; Tian L; Wang M; Li C; Huang Q
Hum Pathol; 2013 Oct; 44(10):2180-7. PubMed ID: 23845466
[TBL] [Abstract][Full Text] [Related]
29. KLF4 and NANOG are prognostic biomarkers for triple-negative breast cancer.
Nagata T; Shimada Y; Sekine S; Moriyama M; Hashimoto I; Matsui K; Okumura T; Hori T; Imura J; Tsukada K
Breast Cancer; 2017 Mar; 24(2):326-335. PubMed ID: 27300169
[TBL] [Abstract][Full Text] [Related]
30. S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer.
Maierthaler M; Kriegsmann M; Peng C; Jauch S; Szabo A; Wallwiener M; Rom J; Sohn C; Schneeweiss A; Sinn HP; Yang R; Burwinkel B
Exp Mol Pathol; 2015 Aug; 99(1):180-7. PubMed ID: 26112095
[TBL] [Abstract][Full Text] [Related]
31. ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer.
Wang J; Zhang C; Chen K; Tang H; Tang J; Song C; Xie X
Breast Cancer Res Treat; 2015 Jul; 152(2):255-69. PubMed ID: 26070269
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers.
Bayoglu IV; Kucukzeybek BB; Kucukzeybek Y; Varol U; Yildiz I; Alacacioglu A; Akyol M; Demir L; Dirican A; Yildiz Y; Salman T; Tarhan MO
Biomed Pharmacother; 2015 Mar; 70():190-5. PubMed ID: 25776500
[TBL] [Abstract][Full Text] [Related]
33. Triple-negative breast cancer survival in Iranian patients.
Aghili M; Lashkari M; Farrokhpey AH; Izadi S
Acta Med Iran; 2013 Sep; 51(8):560-6. PubMed ID: 24026994
[TBL] [Abstract][Full Text] [Related]
34. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes.
Elfgen C; Reeve K; Moskovszky L; Güth U; Bjelic-Radisic V; Fleisch M; Tausch C; Varga Z
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2051-2059. PubMed ID: 31270600
[TBL] [Abstract][Full Text] [Related]
36. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.
Ehmsen S; Hansen LT; Bak M; Brasch-Andersen C; Ditzel HJ; Leth-Larsen R
Int J Cancer; 2015 Nov; 137(9):2093-103. PubMed ID: 25912829
[TBL] [Abstract][Full Text] [Related]
37. Transgelin: a potentially useful diagnostic marker differentially expressed in triple-negative and non-triple-negative breast cancers.
Rao D; Kimler BF; Nothnick WB; Davis MK; Fan F; Tawfik O
Hum Pathol; 2015 Jun; 46(6):876-83. PubMed ID: 25841305
[TBL] [Abstract][Full Text] [Related]
38.
Stüber T; Monjezi R; Wallstabe L; Kühnemundt J; Nietzer SL; Dandekar G; Wöckel A; Einsele H; Wischhusen J; Hudecek M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303620
[TBL] [Abstract][Full Text] [Related]
39. Vimentin as a poor prognostic factor for triple-negative breast cancer.
Yamashita N; Tokunaga E; Kitao H; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Aishima S; Morita M; Maehara Y
J Cancer Res Clin Oncol; 2013 May; 139(5):739-46. PubMed ID: 23354842
[TBL] [Abstract][Full Text] [Related]
40. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
